({3-[4-(Difluoro-p-tolylmethyl)phenoxyl]-3-phenylpropyl}methylamino)acetic acid ethyl ester | 497932-12-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: ({3-[4-(Difluoro-p-tolylmethyl)phenoxyl]-3-phenylpropyl}methylamino)acetic acid ethyl ester
• 英文别名: Ethyl 2-[[3-[4-[difluoro-(4-methylphenyl)methyl]phenoxy]-3-phenylpropyl]-methylamino]acetate
• CAS: 497932-12-4
• 化学式: C₂₈H₃₁F₂NO₃
• 分子量: 467.556
• InChiKey: GQCGKJALUCZQFF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.6
• 重原子数：
  34
• 可旋转键数：
  12
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  38.8
• 氢给体数：
  0
• 氢受体数：
  6

文献信息

• Difluoromethylene aromatic ethers as inhibitors of glycine transport
  申请人：Pfizer Inc.

  公开号：US20030045569A1

  公开（公告）日：2003-03-06

  This invention relates to a series of difluoromethylene aromatic ethers of the formula 1 wherein ring A and X and Y are defined as in the specification, that exhibit activity as glycine transport inhibitors, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their use for the enhancement of cognition and the treatment of the positive and negative symptoms of schizophrenia and other psychoses in mammals, including humans.

  这项发明涉及一系列二氟甲亚烷芳基醚化合物，其化学式如下所示：其中环A以及X和Y的定义如规范中所述，这些化合物表现出作为甘氨酸转运抑制剂的活性，它们的药学上可接受的盐，含有它们的药物组合物，以及它们用于增强认知和治疗哺乳动物，包括人类，的精神分裂症和其他精神病阳性和阴性症状的用途。
• Difluoromethylene aromatic ethers and their use as inhibitors of the glycine type-1 transporter
  申请人：Pfizer Products Inc.

  公开号：EP1284257A2

  公开（公告）日：2003-02-19

  This invention relates to a series of difluoromethylene aromatic ethers of the formula wherein ring A and X and Y are defined as in the specification, that exhibit activity as glycine transport inhibitors, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their use for the enhancement of cognition and the treatment of the positive and negative symptoms of schizophrenia and other central nervous system disorders in mammals, including humans.

  本发明涉及一系列二氟亚甲基芳香族醚，其式为 其中环 A 以及 X 和 Y 的定义如说明书中所述，它们具有作为甘氨酸转运抑制剂的活性、它们的药学上可接受的盐、含有它们的药物组合物，以及它们用于增强哺乳动物（包括人类）的认知能力和治疗精神分裂症及其他中枢神经系统疾病的阳性和阴性症状的用途。
• US6710071B2
  申请人：——

  公开号：US6710071B2

  公开（公告）日：2004-03-23